Norelgestromin
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Norelgestromin: From Contraception to Amenorrhea
One-Sentence Summary
Norelgestromin is the active metabolite of norgestimate, a third-generation progestin used as the progestogen component of a combined transdermal contraceptive patch. The TxGNN model predicts a potential new indication of Amenorrhea, but this direction is currently supported by zero clinical trials and zero publications — and the supplied rationale itself flags the prediction as a likely reverse-causality artifact, since amenorrhea is a documented adverse effect of this drug, not a condition it is known to treat.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on file in this evidence pack (no approved product license found); drug is clinically used as a component of a combined transdermal contraceptive patch |
| Predicted New Indication | Amenorrhea |
| TxGNN Prediction Score | 99.51% |
| Evidence Level | L5 |
| Germany Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Norelgestromin is the active metabolite of norgestimate and acts as a third-generation progestin. Clinically, it is used as a component of a combined transdermal contraceptive patch, where it suppresses gonadotropin secretion, inhibits ovulation, and alters the endometrium to prevent pregnancy. A formally structured DrugBank mechanism-of-action record was not available in this evidence pack; the description above is derived from the drug's known pharmacological class and the rationale accompanying the prediction.
The predicted new indication — amenorrhea — is mechanistically connected to norelgestromin only through its already-established adverse effect profile. Amenorrhea (absent or missed withdrawal bleeding) is a commonly reported reason patients discontinue combined hormonal contraceptives, including the norelgestromin/ethinyl estradiol patch. There is no known mechanism by which norelgestromin would be used therapeutically to treat amenorrhea; a progestin that suppresses the hypothalamic-pituitary-ovarian axis and thins the endometrium is pharmacologically far more consistent with causing amenorrhea than with correcting it.
For this reason, the evidence pack itself flags this prediction as a probable reverse-causality artifact: TxGNN, like other knowledge-graph models, can mislearn a drug–adverse-event edge ("norelgestromin causes amenorrhea") as a drug–indication edge ("norelgestromin treats amenorrhea") — a known pitfall for progestins, where amenorrhea is heavily coded in pharmacovigilance data. The high TxGNN score (99.51%) should therefore not be read as an endorsement of therapeutic plausibility; it more likely reflects the strength of the drug–amenorrhea association driven by adverse-event reporting rather than any treatment signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Germany Market Information
Norelgestromin currently has no marketing authorization on file (market status: Not Marketed, 0 authorizations). No product name, dosage form, or approved-indication data is available in this evidence pack.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The evidence level is L5 (model prediction only, no clinical trials or literature), and the decision stage is S0 — the earliest possible stage, with no safety pre-screening completed.
- The mechanistic rationale itself indicates this prediction is more likely a reverse-causality artifact (amenorrhea is a known adverse effect of norelgestromin, not a plausible treatment target) rather than a genuine repurposing signal.
To proceed, the following is needed:
- TFDA/BfArM package insert data (warnings and contraindications) — currently a Blocking data gap (DG001), required before any S1 safety pre-screening can begin
- Confirmed mechanism of action from the DrugBank API — currently a High-severity data gap (DG002)
- An independent pharmacovigilance/literature review to explicitly test and either confirm or refute the reverse-causality hypothesis before any further evaluation
- If the reverse-causality hypothesis is not resolved, this candidate should be deprioritized rather than advanced past S0
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.